![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NAV2 |
Gene summary for NAV2 |
![]() |
Gene information | Species | Human | Gene symbol | NAV2 | Gene ID | 89797 |
Gene name | neuron navigator 2 | |
Gene Alias | HELAD1 | |
Cytomap | 11p15.1 | |
Gene Type | protein-coding | GO ID | GO:0001976 | UniProtAcc | A7E2D6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
89797 | NAV2 | CCI_2 | Human | Cervix | CC | 1.13e-02 | 6.01e-01 | 0.5249 |
89797 | NAV2 | CCI_3 | Human | Cervix | CC | 2.07e-08 | 8.18e-01 | 0.516 |
89797 | NAV2 | AEH-subject1 | Human | Endometrium | AEH | 2.56e-21 | 6.49e-01 | -0.3059 |
89797 | NAV2 | AEH-subject2 | Human | Endometrium | AEH | 1.42e-14 | 5.80e-01 | -0.2525 |
89797 | NAV2 | AEH-subject4 | Human | Endometrium | AEH | 5.58e-08 | 4.92e-01 | -0.2657 |
89797 | NAV2 | AEH-subject5 | Human | Endometrium | AEH | 9.17e-25 | 8.33e-01 | -0.2953 |
89797 | NAV2 | EEC-subject1 | Human | Endometrium | EEC | 5.47e-48 | 1.03e+00 | -0.2682 |
89797 | NAV2 | EEC-subject2 | Human | Endometrium | EEC | 1.65e-11 | 5.01e-01 | -0.2607 |
89797 | NAV2 | EEC-subject3 | Human | Endometrium | EEC | 5.93e-21 | 7.44e-01 | -0.2525 |
89797 | NAV2 | EEC-subject4 | Human | Endometrium | EEC | 7.20e-19 | 7.22e-01 | -0.2571 |
89797 | NAV2 | EEC-subject5 | Human | Endometrium | EEC | 1.06e-12 | 5.12e-01 | -0.249 |
89797 | NAV2 | GSM5276934 | Human | Endometrium | EEC | 2.05e-02 | 2.90e-01 | -0.0913 |
89797 | NAV2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 5.76e-05 | 1.53e-01 | -0.1869 |
89797 | NAV2 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 5.44e-04 | 1.93e-01 | -0.1875 |
89797 | NAV2 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.90e-05 | 2.13e-01 | -0.1883 |
89797 | NAV2 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.99e-07 | 1.16e-01 | -0.1916 |
89797 | NAV2 | LZE4T | Human | Esophagus | ESCC | 2.31e-09 | 2.62e-01 | 0.0811 |
89797 | NAV2 | LZE5T | Human | Esophagus | ESCC | 1.57e-03 | 3.16e-01 | 0.0514 |
89797 | NAV2 | LZE7T | Human | Esophagus | ESCC | 2.39e-04 | 3.68e-01 | 0.0667 |
89797 | NAV2 | LZE8T | Human | Esophagus | ESCC | 1.37e-04 | 9.78e-02 | 0.067 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
GO:003239214 | Esophagus | ESCC | DNA geometric change | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
GO:003250813 | Esophagus | ESCC | DNA duplex unwinding | 58/8552 | 84/18723 | 1.23e-05 | 1.14e-04 | 58 |
GO:00323922 | Liver | NAFLD | DNA geometric change | 18/1882 | 90/18723 | 3.34e-03 | 2.93e-02 | 18 |
GO:003239211 | Liver | HCC | DNA geometric change | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:00325081 | Liver | HCC | DNA duplex unwinding | 49/7958 | 84/18723 | 2.46e-03 | 1.19e-02 | 49 |
GO:0007626 | Lung | AIS | locomotory behavior | 31/1849 | 179/18723 | 1.39e-03 | 1.70e-02 | 31 |
GO:00030731 | Lung | MIAC | regulation of systemic arterial blood pressure | 12/967 | 96/18723 | 3.86e-03 | 4.71e-02 | 12 |
GO:00323925 | Oral cavity | OSCC | DNA geometric change | 59/7305 | 90/18723 | 3.03e-07 | 4.63e-06 | 59 |
GO:00325083 | Oral cavity | OSCC | DNA duplex unwinding | 55/7305 | 84/18723 | 8.05e-07 | 1.12e-05 | 55 |
GO:003239221 | Oral cavity | EOLP | DNA geometric change | 21/2218 | 90/18723 | 1.63e-03 | 1.09e-02 | 21 |
GO:003250812 | Oral cavity | EOLP | DNA duplex unwinding | 19/2218 | 84/18723 | 3.84e-03 | 2.13e-02 | 19 |
GO:003239231 | Oral cavity | NEOLP | DNA geometric change | 19/2005 | 90/18723 | 2.81e-03 | 1.73e-02 | 19 |
GO:003250821 | Oral cavity | NEOLP | DNA duplex unwinding | 18/2005 | 84/18723 | 3.02e-03 | 1.84e-02 | 18 |
GO:00323924 | Prostate | BPH | DNA geometric change | 26/3107 | 90/18723 | 2.46e-03 | 1.33e-02 | 26 |
GO:00325082 | Prostate | BPH | DNA duplex unwinding | 24/3107 | 84/18723 | 4.13e-03 | 2.04e-02 | 24 |
GO:003239212 | Prostate | Tumor | DNA geometric change | 27/3246 | 90/18723 | 2.15e-03 | 1.22e-02 | 27 |
GO:003250811 | Prostate | Tumor | DNA duplex unwinding | 25/3246 | 84/18723 | 3.47e-03 | 1.79e-02 | 25 |
GO:00323927 | Skin | AK | DNA geometric change | 23/1910 | 90/18723 | 2.53e-05 | 4.54e-04 | 23 |
GO:00325085 | Skin | AK | DNA duplex unwinding | 21/1910 | 84/18723 | 7.93e-05 | 1.09e-03 | 21 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAV2 | SNV | Missense_Mutation | c.4097G>C | p.Gly1366Ala | p.G1366A | Q8IVL1 | protein_coding | deleterious(0.04) | benign(0.194) | TCGA-33-4586-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
NAV2 | SNV | Missense_Mutation | c.6722N>T | p.Gly2241Val | p.G2241V | Q8IVL1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-6737-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | gemcitabine | PD | |
NAV2 | SNV | Missense_Mutation | novel | c.5333A>T | p.Glu1778Val | p.E1778V | Q8IVL1 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-33-A4WN-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NAV2 | SNV | Missense_Mutation | c.2980G>A | p.Asp994Asn | p.D994N | Q8IVL1 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-34-2600-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NAV2 | SNV | Missense_Mutation | novel | c.6478N>T | p.Gly2160Cys | p.G2160C | Q8IVL1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-37-3789-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NAV2 | SNV | Missense_Mutation | rs755116010 | c.5383C>T | p.Arg1795Cys | p.R1795C | Q8IVL1 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-37-4135-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
NAV2 | SNV | Missense_Mutation | c.1583N>T | p.Ala528Val | p.A528V | Q8IVL1 | protein_coding | tolerated_low_confidence(0.08) | benign(0.003) | TCGA-39-5021-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | etoposide | PD | |
NAV2 | SNV | Missense_Mutation | c.95N>A | p.Ala32Glu | p.A32E | Q8IVL1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.09) | TCGA-39-5027-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NAV2 | SNV | Missense_Mutation | novel | c.907N>G | p.Thr303Ala | p.T303A | Q8IVL1 | protein_coding | tolerated(0.5) | benign(0) | TCGA-52-7811-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
NAV2 | SNV | Missense_Mutation | novel | c.793N>G | p.Gln265Glu | p.Q265E | Q8IVL1 | protein_coding | tolerated(0.07) | possibly_damaging(0.621) | TCGA-56-8503-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |